Statistics for OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
Total visits
| views | |
|---|---|
| OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS. | 50 |
Total visits per month
| views | |
|---|---|
| January 2025 | 2 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| 2022_EULAR-OP0147-SLE-DAS_remission_and_low_disease_activity_states_are_associated_with_improved_health-related.pdf(legacy) | 15 |
| 2022_EULAR-OP0147-SLE-DAS_remission_and_low_disease_activity_states_are_associated_with_improved_health-related.pdf | 2 |
Top country views
| views | |
|---|---|
| United States | 13 |
| Portugal | 8 |
| China | 6 |
| India | 4 |
| Australia | 3 |
| Canada | 3 |
| United Kingdom | 2 |
| Japan | 2 |
| Ukraine | 2 |
| Bulgaria | 1 |
| Brazil | 1 |
| Germany | 1 |
| Latvia | 1 |
| Taiwan | 1 |